Messenger RNA-1273 Moderna COVID-19 Vaccination as Potential Trigger for Case of New Onset Pemphigus Vulgaris

Main Article Content

Sara Holt
Largo Medical Center

Abigail Meckley
Rocky Vista University College of Osteopathic Medicine, Parker, Colorado

Taylor Harp
Rocky Vista University College of Osteopathic Medicine, Parker, Colorado

David Esguerra
HCA Healthcare/USF Morsani College of Medicine GME Programs, Largo Medical Center, Largo, Florida

Keywords

Pemphigus vulgaris, COVID-19 mRNA vaccine, Moderna vaccine, autoimmune disorder, autoimmune bullous disease, mRNA-1273 vaccine

Abstract

As vaccination against Coronavirus 2019 (COVID-19) remains a worldwide initiative, so does describing its associated adverse effects. While there have been many reports detailing various dermatologic adverse events, autoimmune bullous disorders following vaccination are less well described.1 Pemphigus vulgaris (PV) is an autoimmune bullous disease of the skin and mucous membranes that has many known triggers, including vaccination.2 To our knowledge, there are at least six cases of pemphigus vulgaris developing following SARS-Cov-2 vaccination.3 Here we describe a case of new onset PV following COVID-19 vaccination with the mRNA-1273 (Moderna) vaccine. Because this disease carries significant morbidity and mortality, we hope this report serves as a reminder that while vaccination remains a global priority, continued documentation and recognition of novel vaccination side effects by clinicians is essential.

References

1. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46-55. https://doi:10.1016/j.jaad.2021.03.092

2. Solimani F, Mansour Y, Didona D, Dilling A, Ghoreschi K, Meier K. Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2. J Eur Acad Dermatol Venereol. 2021;35(10):e649-e651. doi:10.1111/jdv.17480

3. Calabria E, Canfora F, Mascolo M, Varricchio S, Mignogna MD, Adamo D. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: a case report of Pemphigus Vulgaris and a literature review. Pathol Res Pract. 2022 Apr;232:153834. doi: 10.1016/j.prp.2022.153834

4. United States Department of Health and Human Services (DHHS), Public Health Service (PHS), Centers for Disease Control (CDC) / Food and Drug Administration (FDA), Vaccine Adverse Event Reporting System (VAERS) 1990 - 12/03/2021, CDC WONDER On-line Database. Accessed at http://wonder.cdc.gov/vaers.html on Dec 12, 2021

Article Sidebar

PDF
Published
Sep 12, 2022
DOI https://doi.org/10.25251/skin.6.5.11

Article Details

How to Cite
Holt, S., Meckley, A., Harp, T., & Esguerra, D. . (2022). Messenger RNA-1273 Moderna COVID-19 Vaccination as Potential Trigger for Case of New Onset Pemphigus Vulgaris. SKIN The Journal of Cutaneous Medicine, 6(5), 415–417. https://doi.org/10.25251/skin.6.5.11
Issue
Vol. 6 No. 5 (2022)
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.